Financial Results for the Fiscal Year Ended March 31, 2026 May 12, 2026 Stock Exchange Listings : Tokyo Stock Exchange Company name Securities code Representative Inquiries TEL Date of general shareholders' meeting (as planned) Annual securities…
Financial Results for the Fiscal Year Ended March 31, 2026
May 12, 2026
Stock Exchange Listings : Tokyo Stock Exchange
Company name
Securities code
Representative
Inquiries
TEL
Date of general shareholders' meeting (as planned)
Annual securities report filing date (as planned)
Supplemental material of annual results
Convening briefing of financial results
: JMS Co., Ltd.
URL https://www.jms.cc/english/
: 7702
: Ryuji Katsura, President and Representative Director
: Yoshiki Ochiai, Executive Officer, Head of Corporate Affairs Division
: +81-82-243-5844
: Jun 23, 2026
: Jun 22, 2026
Dividend payable date
: Jun 24, 2026
: Yes
: Yes
(Note: Amounts below are rounded down to the nearest million yen)
- Consolidated Financial Highlights for the Year Ended March 31, 2026 (From April 1, 2025 to March 31, 2026)
(1) Consolidated Financial Results
(%: change from the same previous period)
Profit attributable to
Net sales
Operating profit
Ordinary profit
owners of parent
Millions of
Millions of
Millions of
Millions of yen
%
%
%
%
yen
yen
yen
(56.3)
―
Year ended March 31, 2026
65,845 (5.6)
381
356 (30.8)
(783)
―
―
Year ended March 31, 2025
69,749 6.8
872
514 252.7
89
(Note) Comprehensive income: Year ended March 31, 2026: 1,264 million yen [116.5%], Year ended March 31 2025: 584 million yen [(76.0)%]
Basic earnings
per share
Diluted earnings
per share
Rate of return
on equity
Yen
(31.97)
3.65
Yen
%
Year ended March 31, 2026
Year ended March 31, 2025
Ordinary income
to total assets
ratio
%
0.4
0.6
Operating income
to net sales ratio
―
(1.9)
―
0.2
(Note) Equity in earnings of affiliates: Year ended March 31, 2026: 235 million yen, Year ended March 31, 2025: 201 million yen.
(2) Consolidated Financial Positions
Total assets
Millions of yen
As at March 31, 2026
83,067
As at March 31, 2025
81,432
Net assets
Millions of yen
41,791
40,927
Capital adequacy ratio
%
50.2
50.1
%
0.6
1.3
Net assets per share
Yen
1,701.18
1,666.51
(Note) Owner's equity: As at March 31, 2026: 41,730 million yen, As at March 31, 2025: 40,835 million yen.
(3) Consolidated Cash Flows
Year ended March 31, 2026
Year ended March 31, 2025
Cash flows from
operating activities
Millions of yen
1,584
1,467
Cash flows from
investing activities
Millions of yen
(2,250)
(3,132)
Cash flows from
financing activities
Millions of yen
2,687
(3,186)
Cash and cash equivalents
at end of period
Millions of yen
7,717
5,507
- Dividends
Dividend per share
Yen
―
―
Yen
8.50
8.50
Yen
―
―
Yen
8.50
8.50
Yen
17.00
17.00
Ratio of total amount of
Payout ratio
dividends to net assets
(Consolidated)
(Consolidated)
Millions of yen
%
%
416
465.8
1.0
416
―
1.0
―
8.50
―
8.50
17.00
69.4
1st quarter 2nd quarter 3rd quarter Year end Annual
Year ended March 31, 2025
Year ended March 31, 2026
Year ending March 31, 2027
(forecast)
Total dividend
paid
- Consolidated Forecast for the Year Ending March 31, 2027 (From April 1, 2026 to March 31, 2027)
(%: change from the same previous period)
Profit attributable to Basic earnings
owners of parent
per share
Millions of yen
% Millions of yen
% Millions of yen
% Millions of yen
%
Yen
31,600 (1.9)
350
―
300
―
200
―
8.16
66,000
0.2
1000 162.1
900 152.4
600
―
24.47
Net sales
Half year ending September 30, 2026
Year ending March 31, 2027
Operating profit
Ordinary profit
The aforementioned projections are based on the information currently available, and may contain some uncertainties.
The final results might be significantly different from the aforementioned projections due to changes in business conditions.
Page 1 of 11
JMS (7702) Financial Results for the Fiscal Year Ended March 31, 2026
- Overview of business performance
(1) Overview of business performance of this fiscal year
JMS strives to improve the quality of corporate management and the corporate value, in order ' To be a bridge for the
people who give and seek medical care, and to bring a smile to people by contributing to a healthy and better life'
under our Founding Spirit of 'For People’s Precious Life'. JMS focused on four fields of business activities such as
infusion & enteral nutrition, dialysis, cardiovascular, and blood management & cell therapy and promotes product
development, production and sales.
The business environment surrounding the JMS Group is characterized by growing demand for high value-added
medical devices, mainly for home healthcare and diagnostic/treatment support, against the backdrop of an aging
population and an increase in chronic diseases. Additionally, regulations regarding the safety and reliability of
medical devices are becoming increasingly stringent internationally, requiring appropriate responses to new laws and
regulations in each country and region. Furthermore, there remains uncertainty in the global business environment
due to geopolitical risks and rising raw material prices. On the other hand, the medical device market is expected to
continue stable growth over the medium to long term, supported by structural growth factors such as global
population aging, increased health consciousness, accelerated medical infrastructure development in emerging
countries, and promotion of digitalization in healthcare, particularly in developed countries. Especially in
telemedicine and home healthcare, advances are being made in the spread of online medical consultations, efficiency
improvements in medical settings through collection and analysis of medical data, and advancement of diagnosis and
treatment support utilizing AI (artificial intelligence) technology.
In response to these changes in the business environment, the JMS Group will strive to achieve sustainable growth
and enhance corporate value by providing optimal solutions that integrate medical devices and digital technology.
During this consolidated fiscal year, in Japan, although sales of Medical Gloves and Urinary Drainage-related
products decreased, sales of Closed Drug Mixing/Infusion Systems, which we are promoting as a priority business,
and Dysphagia-related products, for which demand is expanding, continued to grow. In overseas markets, while sales
of AV Fistula Needles remained strong, sales of Blood Bags and Apheresis Kits for North America decreased.
As a result, net sales for this consolidated fiscal year decreased by 3,904 million yen from the previous consolidated
fiscal year to 65,845 million yen (down 5.6% year-over-year).
Regarding profits, although the effect of increased sales of AV Fistula Needles, Closed Drug Mixing/Infusion Systems,
and Dysphagia-related products contributed, the impact of decreased sales of Blood Bags and Apheresis Kits resulted
in operating profit of 381 million yen, down by 491 million yen from the previous consolidated fiscal year (down
56.3% year-over-year). While equity in earnings of affiliates was recorded, interest expenses and foreign exchange
losses were posted, resulting in ordinary profit of 356 million yen (down 30.8% year-over-year). Furthermore, as part
of structural reforms to reorganize overseas production bases, business restructuring losses were recorded as
extraordinary losses at the Korean production facility, resulting in net loss attributable to owners of the parent of 783
million yen (compared to net profit of 89 million yen in the previous fiscal year).
Business performance by geographical segment.
(i) Japan
Although sales of Dysphagia-related products and Closed Drug Mixing/Infusion Systems were strong, decreases in
sales of Acute Blood Purification Devices and Hemodialysis Machines for China resulted in net sales of 44,759
million yen (down 2.8% year-over-year). Segment profit was 949 million yen (down 36.0% year-over-year) due to
decreased sales impact and increases in commission fees and research and development expenses.
(ii) Singapore
Net sales decreased to 23,726 million yen (down 10.6% year-over-year) due to decreased sales of Apheresis Kits for
North America and Blood Bags for Africa and Asia. Segment loss was 47 million yen (compared to a loss of 200
million yen in the previous fiscal year) as a result of decreased sales of mainstay products, although foreign exchange
losses decreased.
Page 2 of 11
JMS (7702) Financial Results for the Fiscal Year Ended March 31, 2026
(iii) China
Net sales decreased to 3,985 million yen (down 4.3% year-over-year) due to decreased sales of AV Fistula Needles
within China. Segment profit was 87 million yen (compared to a loss of 28 million yen in the previous fiscal year)
due to cost reduction and expense reduction effects.
(iv) Philippines
Net sales decreased to 3,335 million yen (down 8.9% year-over-year) due to decreased sales of Blood Bags and
Apheresis Kits for Asia. Segment loss was 727 million yen (compared to a loss of 415 million yen in the previous
fiscal year) due to lower operating rates accompanying decreased Blood Bag sales and increased labor costs.
(v) Germany
Net sales decreased to 3,956 million yen (down 11.5% year-over-year) due to decreased sales of Dialysis Therapy
Chairs, although sales of AV Fistula Needles for Europe were strong. Segment profit was 473 million yen (up 4.1%
year-over-year) despite decreased sales impact, due to administrative expense reduction effects.
(vi) Others
Net sales increased to 5,929 million yen (up 17.5% year-over-year) due to increased sales of AV Fistula Needles and
Scalp Vein Needles for North America, despite decreased sales of Infusion Sets within Korea. Segment profit was 24
million yen (compared to a loss of 385 million yen in the previous fiscal year).
(2) Overview of the financial condition
Total assets for this consolidated fiscal year increased by 1,635 million yen from the end of the previous consolidated
fiscal year to 83,067 million yen. Details of assets, liabilities and net assets are as follows.
(Assets)
Current assets increased by 1,611 million yen from the end of the previous consolidated fiscal year to 47,385 million
yen. This was mainly due to an increase in cash and deposits resulting from borrowings. Non-current assets increased
by 23 million yen from the end of the previous consolidated fiscal year to 35,682 million yen. This was mainly due
to an increase in the market valuation of investment securities.
(Liabilities)
Current liabilities increased by 1,053 million yen from the end of the previous consolidated fiscal year to 26,682
million yen. This was mainly due to an increase in short-term loans payable. Non-current liabilities decreased by 281
million yen from the end of the previous consolidated fiscal year to 14,593 million yen. This was mainly due to a
decrease in retirement benefit liabilities accompanying the reorganization of the Korean production facility.
(Net assets)
Net assets increased by 864 million yen from the end of the previous consolidated fiscal year to 41,791 million yen.
This was mainly due to changes in foreign currency translation adjustments. The equity ratio increased by 0.1
percentage points from the end of the previous consolidated fiscal year to 50.2%.
(3) Overview of the cash flows
Cash and cash equivalents (hereinafter referred to as "funds") at the end of this consolidated fiscal year increased by
2,209 million yen from the previous consolidated fiscal year to 7,717 million yen. Cash flows from various activities
are described in more detail below.
(Cash flows from operating activities)
Net cash provided by operating activities was 1,584 million yen, an increase of 116 million yen from the previous
consolidated fiscal year. This was mainly due to changes in inventories.
(Cash flows from investing activities)
Net cash used in investing activities was 2,250 million yen, a decrease of 882 million yen from the previous
consolidated fiscal year. This was mainly due to proceeds from sales of investment securities.
(Cash flows from financing activities)
Net cash provided by financing activities was 2,687 million yen, an increase of 5,873 million yen from the
previous consolidated fiscal year. This was mainly due to the net change in borrowings.
Page 3 of 11
JMS (7702) Financial Results for the Fiscal Year Ended March 31, 2026
(4) Overview of consolidated business forecast
Regarding the future outlook, although conditions differ by country and region, demand is expected to recover and
expand, especially overseas. On the other hand, both domestically and internationally, the business environment is
expected to become increasingly severe, with intensified sales competition, declining sales prices, risks of losing
major customers, as well as anticipated cost increases due to rising transportation fares, raw material prices, and
wage increases.
Moreover, with the heightened geopolitical tensions, particularly in the Middle East, there are concerns about
continued uncertainty in the business environment, including rising energy and raw material prices, logistics
disruptions, and impacts on raw material procurement.
Under these circumstances, as the final year of Medium-term Management Plan 2027, the JMS Group will steadily
translate the structural reforms and growth strategies implemented thus far into tangible results and ensure
improvements in profitability. At the same time, we will absorb the impact of rising costs through the promotion of
price pass-on and further thoroughgoing cost reductions, while working to enhance corporate value and achieve
sustainable growth by responding to societal demands.
The forecast of consolidated financial results for the next fiscal year (ending March 2027) is as follows.
< Consolidated business forecast >
Result of last fiscal year ended
Mar. 2026
Forecast of current fiscal year
ending Mar. 2027
(Unit: million yen)
Changes from same previous
period
65,845
66,000
0.2
Operating profit
381
1,000
162.1
Ordinary profit
356
900
152.4
Profit attributable to owners of
parent
(783)
600
―
Net sales
Exchange rate for the forecast: 1USD=150yen, 1EUR=175yen, 1SGD=117yen.
Page 4 of 11
JMS (7702) Financial Results for the Fiscal Year Ended March 31, 2026
- Consolidated Financial Statements
Consolidated Balance Sheet
JMS CO., LTD. and Consolidated Subsidiaries
(Millions of yen)
As at March 31,
2025
Assets
Current assets
Cash and deposits
Notes receivable - trade
Accounts receivable - trade
Merchandise and finished goods
Work in process
Raw materials and supplies
Other
Allowance for doubtful accounts
Total current assets
Non-current assets
Property, plant and equipment
Buildings and structures
Accumulated depreciation
Buildings and structures, net
Machinery, equipment and vehicles
Accumulated depreciation
Machinery, equipment and vehicles, net
Tools, furniture and fixtures
Accumulated depreciation
Tools, furniture and fixtures, net
Land
Leased assets
Accumulated depreciation
Leased assets, net
Right of use assets
Accumulated depreciation
Right of use assets,net
Construction in progress
Total property, plant and equipment
Intangible assets
Goodwill
Other
Total intangible assets
Investments and other assets
Investment securities
Deferred tax assets
Other
Allowance for doubtful accounts
Total investments and other assets
Total non-current assets
Total assets
Page 5 of 11
As at March 31,
2026
5,511
1,282
17,353
10,913
3,667
6,106
945
(7)
45,773
7,721
1,280
17,374
9,838
3,818
6,547
808
(4)
47,385
26,738
(16,896)
9,841
40,153
(31,331)
8,821
13,836
(11,848)
1,988
2,828
449
(83)
365
3,149
(1,016)
2,132
2,311
28,291
27,543
(17,915)
9,627
42,736
(33,763)
8,972
14,271
(12,367)
1,904
2,853
529
(150)
378
3,282
(1,322)
1,960
2,001
27,698
296
647
943
264
718
982
5,437
391
669
(75)
6,423
35,658
81,432
6,122
272
684
(77)
7,001
35,682
83,067
JMS (7702) Financial Results for the Fiscal Year Ended March 31, 2026
Consolidated Balance Sheet
JMS CO., LTD. and Consolidated Subsidiaries
(Millions of yen)
As at March 31,
2025
Liabilities
Current liabilities
Notes and accounts payable - trade
Short-term borrowings
7,951
5,072
Current portion of long-term borrowings
Lease liabilities
Accounts payable - other
Income taxes payable
Contract liabilities
Provision for bonuses
Other
Total current liabilities
6,002
301
4,200
357
125
1,040
575
25,629
As at March 31,
2026
5,704
8,330
6,141
343
3,903
205
112
1,051
890
26,682
Non-current liabilities
Long-term borrowings
Lease liabilities
Deferred tax liabilities
Provision for retirement benefits for directors (and other officers)
Retirement benefit liability
11,793
1,382
177
171
574
Asset retirement obligations
Other
Total non-current liabilities
Total liabilities
329
446
14,875
40,504
12,005
1,187
198
187
197
374
442
14,593
41,276
Net assets
Shareholders' equity
Share capital
Capital surplus
Retained earnings
Treasury shares
Total shareholders' equity
7,411
10,351
16,723
(177)
34,308
7,411
10,351
15,513
(156)
33,119
Accumulated other comprehensive income
Valuation difference on available-for-sale securities
Foreign currency translation adjustment
Total accumulated other comprehensive income
Non-controlling interests
Total net assets
Total liabilities and net assets
1,073
5,453
6,526
91
40,927
81,432
1,464
7,146
8,611
60
41,791
83,067
Page 6 of 11
JMS (7702) Financial Results for the Fiscal Year Ended March 31, 2026
Consolidated statements of income
JMS CO., LTD. and Consolidated Subsidiaries
(Millions of yen)
Year ended March 31, Year ended March 31,
2025
2026
Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating profit
Non-operating income
Interest income
Dividend income
Share of profit of entities accounted for using equity method
Commission income
Other
Total non-operating income
Non-operating expenses
Interest expenses
Foreign exchange losses
Other
Total non-operating expenses
Ordinary profit
Extraordinary income
Gain on sale of non-current assets
Gain on sale of investment securities
Total extraordinary income
Extraordinary losses
Loss on sale of non-current assets
Loss on abandonment of non-current assets
Impairment losses
Loss on business restructuring
Total extraordinary losses
Profit (loss) before income taxes
Income taxes - current
Income taxes - deferred
Total income taxes
Profit (loss)
Loss attributable to non-controlling interests
Profit (loss) attributable to owners of parent
Page 7 of 11
69,749
53,824
15,924
15,051
872
65,845
50,489
15,355
14,973
381
19
60
201
36
115
433
31
96
235
38
145
547
340
278
172
791
514
407
112
51
572
356
6
75
81
15
310
325
0
33
―
―
34
561
539
15
554
7
(82)
89
10
30
76
934
1,050
(368)
513
(63)
450
(819)
(35)
(783)
JMS (7702) Financial Results for the Fiscal Year Ended March 31, 2026
Consolidated statements of comprehensive income
JMS CO., LTD. and Consolidated Subsidiaries
(Millions of yen)
Year ended March 31, Year ended March 31,
2025
2026
Profit (loss)
Other comprehensive income
Valuation difference on available-for-sale securities
Foreign currency translation adjustment
Total other comprehensive income
Comprehensive income
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
Comprehensive income attributable to non-controlling interests
Page 8 of 11
7
(819)
293
283
577
584
391
1,692
2,084
1,264
666
(82)
1,294
(29)
JMS (7702) Financial Results for the Fiscal Year Ended March 31, 2026
Consolidated statements of changes in net assets
Year ended March 31, 2025
(Millions of yen)
Shareholders' equity
Share capital
Balance at beginning of period
Capital surplus
7,411
Retained earnings
10,351
17,055
Treasury shares
(194)
Total shareholders'
equity
34,623
Changes during period
Dividends of surplus
Profit (loss) attributable to owners of parent
(416)
(416)
89
89
Purchase of treasury shares
(5)
Disposal of treasury shares
(0)
(0)
17
11
Change in ownership interest of parent due to
transactions with non-controlling interests
―
Net changes in items other than shareholders'
equity
Total changes during period
Balance at end of period
―
―
(332)
16
(315)
7,411
10,351
16,723
(177)
34,308
Accumulated other comprehensive income
Valuation difference
on available-for-sale
securities
Balance at beginning of period
Foreign currency
translation
adjustment
779
5,169
Total accumulated
other comprehensive
income
5,949
Non-controlling
interests
174
Total net assets
40,747
Changes during period
(416)
Dividends of surplus
Profit (loss) attributable to owners of parent
89
Purchase of treasury shares
(0)
Disposal of treasury shares
11
Change in ownership interest of parent due to
transactions with non-controlling interests
―
Net changes in items other than shareholders'
equity
293
283
577
(82)
494
Total changes during period
293
283
577
(82)
179
1,073
5,453
6,526
91
40,927
Balance at end of period
Page 9 of 11
JMS (7702) Financial Results for the Fiscal Year Ended March 31, 2026
Consolidated statements of changes in net assets
Year ended March 31, 2026
(Millions of yen)
Shareholders' equity
Share capital
Balance at beginning of period
Capital surplus
7,411
Retained earnings
10,351
16,723
Treasury shares
(177)
Total shareholders'
equity
34,308
Changes during period
Dividends of surplus
(416)
(416)
Profit (loss) attributable to owners of parent
(783)
(783)
Purchase of treasury shares
(9)
Disposal of treasury shares
(0)
(0)
21
12
Change in ownership interest of parent due to
transactions with non-controlling interests
―
Net changes in items other than shareholders'
equity
Total changes during period
Balance at end of period
―
―
(1,210)
21
(1,189)
7,411
10,351
15,513
(156)
33,119
Accumulated other comprehensive income
Valuation difference
on available-for-sale
securities
Balance at beginning of period
1,073
Foreign currency
translation
adjustment
5,453
Total accumulated
other comprehensive
income
6,526
Non-controlling
interests
91
Total net assets
40,927
Changes during period
Dividends of surplus
(416)
Profit (loss) attributable to owners of parent
(783)
Purchase of treasury shares
(0)
Disposal of treasury shares
12
Change in ownership interest of parent due to
transactions with non-controlling interests
Net changes in items other than shareholders'
equity
Total changes during period
Balance at end of period
―
391
1,692
2,084
(31)
2,053
391
1,692
2,084
(31)
864
1,464
7,146
8,611
60
41,791
Page 10 of 11
JMS (7702) Financial Results for the Fiscal Year Ended March 31, 2026
Consolidated statements of cash flows
JMS CO., LTD. and Consolidated Subsidiaries
(Millions of yen)
Year ended March 31, Year ended March 31,
2025
2026
Cash flows from operating activities
Profit (loss) before income taxes
Depreciation
Impairment losses
Loss on business restructuring
Amortization of goodwill
Increase (decrease) in allowance for doubtful accounts
Increase (decrease) in provision for retirement benefits for directors (and other officers)
Increase (decrease) in retirement benefit liability
Interest and dividend income
Interest expenses
Foreign exchange losses (gains)
Share of loss (profit) of entities accounted for using equity method
Loss (gain) on sale of non-current assets
Loss on abandonment of non-current assets
Loss (gain) on sale of investment securities
Decrease (increase) in trade receivables
Decrease (increase) in inventories
Increase (decrease) in trade payables
Increase (decrease) in accrued consumption taxes
Decrease (increase) in other current assets
Increase (decrease) in other current liabilities
Other, net
Subtotal
Interest and dividends received
Interest paid
Income taxes paid
Net cash provided by (used in) operating activities
Cash flows from investing activities
Payments into time deposits
Proceeds from withdrawal of time deposits
Purchase of property, plant and equipment
Proceeds from sale of property, plant and equipment
Purchase of intangible assets
Proceeds from sale of intangible assets
Purchase of shares of subsidiaries and associates
Purchase of investment securities
Proceeds from sale of investment securities
Proceeds from distributions from investment partnerships
Other, net
Net cash provided by (used in) investing activities
Cash flows from financing activities
Proceeds from short-term borrowings
Repayments of short-term borrowings
Proceeds from long-term borrowings
Repayments of long-term borrowings
Purchase of treasury shares
Dividends paid
Repayments of lease liabilities
Net cash provided by (used in) financing activities
Effect of exchange rate change on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Page 11 of 11
561
3,851
―
―
37
(52)
(1)
59
(80)
340
(3)
(201)
(5)
33
(75)
(303)
(1,514)
(833)
(90)
24
289
107
2,143
181
(370)
(486)
1,467
(368)
3,796
76
934
37
(3)
(3)
(400)
(127)
407
(72)
(235)
(5)
30
(310)
490
1,284
(2,376)
141
348
(393)
(659)
2,591
64
(407)
(663)
1,584
(0)
―
(2,898)
11
(142)
―
(98)
(60)
104
9
(58)
(3,132)
(0)
0
(2,476)
116
(183)
0
(41)
(15)
340
0
9
(2,250)
11,295
(12,576)
7,442
(8,690)
(0)
(416)
(240)
(3,186)
54
(4,797)
10,304
5,507
13,672
(10,625)
6,994
(6,668)
(0)
(416)
(268)
2,687
189
2,209
5,507
7,717